BioPharma Resources

Drug Trial Radar · NCT07783425

A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema

A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, ACTIVE- AND PLACEBO-CONTROLLED PHASE 3 MONOTHERAPY STUDY WITH MAINTENANCE PERIOD TO INVESTIGATE THE EFFICACY AND SAFETY OF TILREKIMIG IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,375 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,375

Planned (sponsor's estimate)

Start

Aug 24, 2026

Primary completion

Sep 8, 2028

Study completion Jun 15, 2029

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Aug 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body in adults and adolescents with moderate to severe atopic dermatitis (eczema). Eczema is a condition which can cause dryness, itching, and redness of your skin. The study is seeking participants who: * Are aged 12 years or older. * Were confirmed to have atopic dermatitis (AD) at least 12 months ago. * Are not having an effective treatment result from medicines that are applied on skin for AD. * Are considered by their doctors to have moderate to severe AD. The study treatment period will be 52 weeks. During the 24-week initial treatment period, participants will be randomized to one of three study treatments - tilrekimig, dupilumab, or placebo. Placebo does not have any medicine in it but looks just like the medicine being studied. These treatments will be randomized based on a 2:2:1 ratio. This means out of 1375 participants, about 550 participants will receive tilrekimig, 550 will receive dupilumab, and 275 will receive placebo. This will be followed by a 28-week maintenance period. The last dose of study treatment will be administered at week 48. Some participants will join the long-term extension (LTE) study C4531008 at week 52. A long-term extension study is an additional study that some participants may be able to join after completing the study if they are interested and meet eligibility requirements. It allows researchers to continue collecting information about how well the study medicine works. It also helps them assess how safe it is when used for a longer period of time. Participants who do not join this study will enter a 12-week safety follow-up period. This period ends 16 weeks after their last dose of study treatment.

Conditions

  • Atopic Dermatitis

Interventions

  • TilrekimigDrug

    Subcutaneous Injections at required timepoints

  • DupilumabDrug

    Subcutaneous Injections at required timepoints based on weight and age.

  • Placebo for TilrekimigOther

    Subcutaneous Injections at required timepoints

  • Placebo for DupilumabOther

    Subcutaneous Injections at required timepoints during initial treatment period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Difference in the proportion of Eczema Area and Severity Index (EASI)75 responders between tilrekimig versus placebo.Time frame: Week 16
  2. Difference in the proportion of validated Investigator Global Assessment- Atopic Dermatitis (vIGA-AD) 0/1 responders between tilrekimig versus placebo.Time frame: Week 16

Locations

50 sites in 4 countries. Site status is shown where the registry gives one.

  • AllerVie Clinical Research

    Birmingham, Alabama · Recruiting

  • Cahaba Dermatology & Skin Health Center

    Birmingham, Alabama · Not yet recruiting

  • Alliance Dermatology & MOHS Center

    Phoenix, Arizona · Recruiting

  • Dermatology Trial Associates, Inc.

    Bryant, Arkansas · Recruiting

  • Kern Research, Inc.

    Bakersfield, California · Recruiting

  • First OC Dermatology Research Inc

    Fountain Valley, California · Not yet recruiting

  • Marvel Clinical Research

    Huntington Beach, California · Recruiting

  • Avance Clinical Trials

    Laguna Niguel, California · Recruiting

  • California Allergy & Asthma Medical Group

    Los Angeles, California · Recruiting

  • Northridge Clinical Trials, LLC

    Northridge, California · Recruiting

  • Wolverine Clinical Trials

    Santa Ana, California · Not yet recruiting

  • Direct Helpers Research Center

    Hialeah, Florida · Recruiting

  • Research Associates of South Florida, LLC

    Miami, Florida · Recruiting

  • Global Health Research Center, Inc.

    Miami Lakes, Florida · Recruiting

  • Clinical Neuroscience Solutions, LLC

    Orlando, Florida · Recruiting

  • Advanced Clinical Research Institute

    Tampa, Florida · Not yet recruiting

  • Skin Care Physicians of Georgia

    Macon, Georgia · Recruiting

  • Marietta Dermatology Clinical Research, Inc.

    Marietta, Georgia · Recruiting

  • Treasure Valley Medical Research

    Boise, Idaho · Not yet recruiting

  • Dawes Fretzin Clinical Research Group, LLC

    Indianapolis, Indiana · Recruiting

  • Maryland Laser Skin and Vein

    Hunt Valley, Maryland · Recruiting

  • Revival Research Institute, LLC

    Troy, Michigan · Not yet recruiting

  • Respiratory Medicine Research Institute of Michigan, PLC

    Ypsilanti, Michigan · Recruiting

  • Empire Dermatology

    East Syracuse, New York · Not yet recruiting

  • Vital Prospects Clinical Research Institute., PC

    Tulsa, Oklahoma · Recruiting

  • Oregon Medical Research Center

    Portland, Oregon · Not yet recruiting

  • Best Skin Research, LLC

    Camp Hill, Pennsylvania · Not yet recruiting

  • Clinical Neuroscience Solutions, LLC.

    Memphis, Tennessee · Recruiting

  • Arlington Research Center

    Arlington, Texas · Recruiting

  • Dermatology Treatment and Research Center

    Dallas, Texas · Recruiting

  • Derm Texas

    Dallas, Texas · Recruiting

  • Stryde Research-Epiphany Dermatology

    Southlake, Texas · Not yet recruiting

  • Complete Dermatology

    Sugar Land, Texas · Recruiting

  • Alexandria Associates in Dermatology

    Arlington, Virginia · Recruiting

  • Innovaderm Research Inc

    Montreal, Quebec, Canada · Not yet recruiting

  • Katahira Dermatology Urology Clinic

    Kagoshima, Japan · Recruiting

  • Okayama University Hospital

    Okayama, Japan · Not yet recruiting

  • Pansy Skin Clinic

    Saitama, Japan · Not yet recruiting

  • Japan Community Healthcare Organization Chukyo Hospital

    Nagoya, Aichi-ken, Japan · Not yet recruiting

  • Iwate Medical University Hospital

    Yahaba-cho, Iwate, Japan · Not yet recruiting

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.